Abstract
The clinical response to S-1108 was evaluated in 22 cases of respiratory tract infections.
(1) The overall efficacy rate was 90.9%.
(excellent in 2, good in 18, and fair in 2)
(2) The bacteriological eradication rate was 84.6%.
(3) Side effects consisted of one case of diarrhea. Laboratory tests revealed an increase in the eosinophil count in only one case.
Based on the above results, we consider S-1108 to be a useful drug for respiratory tract infections.
